1. Ismail A, Garba I, Muhammad AR, Dede H, et al.
   Elevated cardiovascular risk in people living with HIV: the association with coronary artery calcification and endothelial dysfunction.
   AIDS 2025.
   


2. Sadinski LM, Edwards JK, Herce ME, Avery CL, et al.
   Blood pressure trajectories among people with and without HIV in a US-based prospective cohort study.
   AIDS 2025.
   


3. Zhu W, Huang YA, Patel RR, Kourtis AP, et al.
   Suboptimal laboratory testing at PrEP initiation in the United States, 2022-2023.
   AIDS 2025.
   


4. Armstrong E, Seo E, Boyachuk B, Loutfy M, et al.
   Gut microbiome and healthy aging in HIV: data from the correlates of healthy aging in geriatric HIV (CHANGE HIV) cohort.
   AIDS 2025.
   


5. Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, et al.
   The Bounce-Back Effect: What Happens After Cessation of Low-Dose Semaglutide in People with HIV.
   Clin Infect Dis 2025.
   


6. Hsu M, Shah A, Jordan A, Gold MS, et al.
   Therapeutic Use of Cannabis and Cannabinoids: A Review.
   JAMA 2025.
   


7. Donaldson A, Druker MR, Monaco MC, Stack EH, et al.
   Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells.
   J Clin Invest 2025.
   


8. Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, et al.
   Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
   J Infect Dis 2025.
   


9. Clark ES, Garrido G, Levay A, Schrand B, et al.
   Vaccination against pathogens targeting cell-derived cryptic antigens.
   J Infect Dis 2025.
   


10. Webb NE, Gorman MJ, Parker LJ, Jung W, et al.
    The functional antibody landscape in HIV post-treatment controllers is heterogeneous.
    J Virol 2025.
    


11. Anang S, Zhang S, Ennis A, Ding H, et al.
    Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles.
    J Virol 2025.
    


12. Lodge R, Kmiec D, Kirchhoff F, Cohen EA, et al.
    HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages.
    J Virol 2025.
    


13. Shi M, Chen R, Wu T, Liao Y, et al.
    Single-cell transcriptome profiling reveals immunological fitness of HIV long-term non-progressors.
    J Virol 2025.
    


14. Gopal K, Burnett C, Kharytonchyk S, Emery A, et al.
    RNA splicing patterns contribute to burst size variation among HIV-1-infected Jurkat cell clones.
    J Virol 2025.
    


15. Schutz E.
    "Miraculous" HIV drug to be rolled out after overcoming aid cuts threat.
    BMJ 2025;391:r2452.
    

Display articles in

• Abstract format